Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Silvia Ling, John Allen(Intelligent Health (United Kingdom)), Shaun Fleming(Peter MacCallum Cancer Centre), P. Joy Ho(The University of Sydney), Ammira Al-Shabeeb(The University of Sydney), Alberto Catalano(Royal Prince Alfred Hospital), Edwin Lau(The University of Sydney), Noemi Horvath(South Australia Pathology), Simon J. Harrison(Peter MacCallum Cancer Centre), Aleksandra Nikolić(The University of Sydney), D. Joshua(The University of Sydney), Harry Iland(Royal Prince Alfred Hospital)
Haematologica
October 11, 2011
10.3324/haematol.2011.043331
Cited by 129

Related Papers

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
|The Lancet|2019|635
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
|Leukemia|2009|586
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523